ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: ABMD
- CUSIP: 00365410
- Previous Close: $116.89
- 50 Day Moving Average: $111.44
- 200 Day Moving Average: $116.45
- 52-Week Range: $43,430,000.00 - $79.62
- Trailing P/E Ratio: 109.58
- Foreward P/E Ratio: 66.56
- P/E Growth: 3.88
- Market Cap: $5.09B
- Outstanding Shares: 43,430,000
- Beta: 0.51
- Net Margins: 11.63%
- Return on Equity: 12.35%
- Return on Assets: 10.54%
Companies Related to ABIOMED:
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 5.66%
- Quick Ratio: 5.12%
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?
5 brokers have issued twelve-month price objectives for ABIOMED's shares. Their forecasts range from $125.00 to $170.00. On average, they expect ABIOMED's stock price to reach $147.00 in the next year.
When will ABIOMED announce their earnings?
ABIOMED is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about ABIOMED stock?
Here are some recent quotes from research analysts about ABIOMED stock:
According to Zacks Investment Research, "ABIOMED Inc. posted a stellar third quarter of fiscal 2017, beating the Zacks Consensus Estimate on both the counts. Over the past six months ABIOMED has outperformed the broader industry trends in terms of price performance. However, an unfavorable estimate revision trend for the current quarter indicates looming concern ahead of the stock. Intensifying competition in the niche markets is likely to mar the company’s prospects over the long haul. Although Abiomed’s significant international presence helps broaden its customer base, fluctuations in currency exchange rates may impact the company’s international sales. Nevertheless, the flagship Impella product line is a significant growth catalyst for the company." (1/30/2017)
Jefferies Group LLC analysts commented, "We hosted ABMD management for a series of meetings. As can be expected for a company that is growing revenue 40%+ and for a stock that has increased 33% this year (after 137% last year), the discussions focused on the sustainability of the company’s growth prospects. The outlook remains very encouraging and we offer some observations below. ABMD remains a top pick. ABMD remains at top pick. There are few growth stories that rival ABMD for large, under penetrated markets; established reimbursement; and no appreciable competition. Since the first PMA approval five quarters ago, the company has seen US Impella revenue growth average 49%. The company still only sells about 15k pumps a year in the US despite a market opportunity that is over 200k, a penetration rate of just 7%." (8/9/2016)
Leerink Swann analysts commented, "SGNT reported "messy" Q1 results on soft revs ($68M, -7% vs JEF, -9% vs cons) & one-off expenses related to the SCP divestiture. Mgt reaffirmed FY16 guidance despite these results, but achieving this forecast now relies even more heavily on the co’s expected 5-8 ANDA approvals in 2H16. Elsewhere, mgt discontinued the previously touted iron sucrose program after multiple setbacks but is very focused on executing M&A to bolster the co’s growth profile. Weak Q1 Financials Place a Heavier Onus on New ANDA Approvals to Meet FY16 Guidance: Q1 revs were softer than anticipated ($68M, -7% vs JEF, -9% vs cons) as a weak cough/cold season weighed on anti-infective revs (~$5M impact). In addition, price erosion in the base oncology business & regulatory issues at a key partner also apparently had an impact ($3M+). Despite these dynamics, mgt reaffirmed FY16 guidance as it expects ~$25M of revs to come from current backorders while $20-60M of new sales (5-8 ANDA approvals) are anticipated from the pipeline. In particular, mgt is increasingly confident in its pipeline following a comprehensive review by an independent consultant." (5/5/2016)
Who owns ABIOMED stock?
ABIOMED's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LLC (4.38%), William Blair Investment Management LLC (2.37%), State Street Corp (2.36%), Brown Capital Management LLC (1.62%), Baillie Gifford & Co. (1.35%) and Renaissance Technologies LLC (1.21%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas, Robert Bowen and William J Bolt.
Who sold ABIOMED stock? Who is selling ABIOMED stock?
ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Federated Investors Inc. PA, State Street Corp, Allianz Asset Management AG, Nicholas Investment Partners LP, Thrivent Financial for Lutherans, Guggenheim Capital LLC and Oberweis Asset Management Inc.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt.
Who bought ABIOMED stock? Who is buying ABIOMED stock?
ABIOMED's stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Russell Investments Group Ltd., William Blair Investment Management LLC, Columbia Wanger Asset Management LLC, Brown Capital Management LLC, Champlain Investment Partners LLC, Congress Asset Management Co. MA and Fred Alger Management Inc..
How do I buy ABIOMED stock?
Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ABIOMED stock cost?
One share of ABIOMED stock can currently be purchased for approximately $117.14.